Alnylam Pharmaceuticals ALNY Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.17B+6.4% | $1.1B-12.2% | $1.25B+61.4% | $773.69M+30.2% | $594.19M+0.2% | ||
| $207.52M-22.5% | $267.72M+35.7% | $197.23M+38.9% | $142.03M+102% | $70.18M-31.6% | ||
| $959.66M+15.7% | $829.31M-21.2% | $1.05B+66.5% | $631.66M+20.5% | $524.01M+6.8% | ||
| 82.2%+6.6pp | 75.6%-8.6pp | 84.2%+2.6pp | 81.6%-6.5pp | 88.2%+5.5pp | ||
| $364.87M-2.0% | $372.22M+3.7% | $358.81M+10.9% | $323.62M+22.1% | $265.12M-11.7% | ||
| $322.55M-0.9% | $325.37M+1.0% | $322.08M-0.4% | $323.31M+34.7% | $239.95M-18.8% | ||
| $898.54M-6.9% | $965.32M+9.6% | $881.04M+11.5% | $789.89M+37.1% | $576.11M-17.5% | ||
| $268.64M+104% | $131.72M-64.2% | $367.98M+2,372% | -$16.2M-190% | $18.08M+117% | ||
| 23%+11.0pp | 12%-17.5pp | 29.5%+31.6pp | -2.1%-5.1pp | 3%+20.8pp | ||
| $69.29M+5.9% | $65.4M+47.3% | $44.4M+10.3% | $40.25M-31.0% | $58.31M+49.6% | ||
| $26.6M-0.1% | $26.63M-7.2% | $28.68M+4.3% | $27.49M-4.1% | $28.67M-7.6% | ||
| -$46.98M-3.4% | -$45.46M+64.8% | -$129.01M-573% | -$19.16M+6.3% | -$20.45M+77.0% | ||
| $221.65M+157% | $86.26M-63.9% | $238.97M+776% | -$35.36M-1,393% | -$2.37M+98.8% | ||
| $15.66M— | —— | -$12.12M-139% | $30.92M+94.7% | $15.88M+114% | ||
| $205.99M+84.7% | $111.54M-55.6% | $251.08M+479% | -$66.28M-263% | -$18.25M+78.2% | ||
| 17.6%+7.5pp | 10.2%-9.9pp | 20.1%+28.7pp | -8.6%-5.5pp | -3.1%+11.0pp | ||
| $1.51+84.1% | $0.82-55.4% | $1.84+461% | -$0.51-264% | -$0.14+78.5% | ||
| $1.55+84.5% | $0.84-56.0% | $1.91+475% | -$0.51-264% | -$0.14+78.5% | ||
| 138.2M+2.6% | 134.7M-1.9% | 137.3M+5.1% | 130.6M+0.7% | 129.7M+1.6% | ||
| 132.9M+1.4% | 131M-0.3% | 131.4M+0.6% | 130.6M+0.7% | 129.7M+1.6% | ||
| $3.6M— | $0-100% | $2.92M+216% | $924K+7.7% | $858K+411% | ||
| $9.19M+608% | $1.3M-76.5% | $5.52M+1,181% | $431K-88.2% | $3.65M+131% | ||
| $201.19M+77.7% | $113.22M-56.3% | $259.26M+542% | -$58.71M-176% | -$21.25M+77.3% | ||
| $9.31M+134% | -$27.17M-585% | $5.6M-42.5% | $9.74M+1.0% | $9.64M+109% | ||
| $13.55M+0.3% | $13.51M-2.2% | $13.8M-1.0% | $13.94M-3.2% | $14.41M+1.7% | ||
| $2.37M— | —— | $1.28M— | —— | $2.97M-52.1% | ||
| $110.42M— | —— | $399.86M+192% | $136.91M+1,742% | $7.43M-87.5% | ||
| -$1.63M— | $0+100% | -$12.54M+4.1% | -$13.08M+52.1% | -$27.32M-113% | ||
| $3.32M— | —— | -$4.98M+55.3% | -$11.14M-79.3% | -$6.22M-632% | ||
| $6.32M-91.1% | $70.99M+242% | $20.74M— | $0-100% | $32.77M+230% | ||
| $64.2M-43.3% | $113.32M+374% | $23.89M+90.1% | $12.57M-81.8% | $68.93M+459% | ||
| $15.71M— | —— | -$448.35M-966% | $51.76M+12.3% | $46.08M+48.7% | ||
| -$25.54M— | $0-100% | $501.11M+454% | -$141.38M-224% | $113.77M+315% | ||
| $70.5M-56.9% | $163.56M-49.7% | $325.11M+109% | $155.73M+229% | -$120.31M-27.1% | ||
| -$3.65M— | $0-100% | $1.13M+430% | -$343K-133% | $1.03M+122% | ||
| -$4.3M-106% | $76.56M+203% | -$74.15M-1,059% | -$6.4M-170% | $9.19M+111% | ||
| $2.99M— | —— | —— | -$18.51M+4.4% | -$19.35M-186% | ||
| $261.63M+10.9% | $235.91M+13.4% | $207.97M-54.7% | $459.56M+14.4% | $401.64M-17.5% | ||
| $21.83M-6.3% | $23.29M+91.8% | $12.14M-15.0% | $14.29M+59.3% | $8.97M-1.4% | ||
| $13.16M-68.4% | $41.7M-46.4% | $77.74M-4.3% | $81.22M+64.5% | $49.37M+36.1% | ||
| $1.17B+6.4% | $1.1B-12.2% | $1.25B+61.4% | $773.69M+30.2% | $594.19M+0.2% | ||
| $70.15M-2.1% | $71.63M-33.8% | $108.21M-3.1% | $111.68M+96.9% | $56.71M-38.1% | ||
| $268.64M+104% | $131.72M-64.2% | $367.98M+2,372% | -$16.2M-190% | $18.08M+117% | ||
| $282.19M+94.3% | $145.22M-62.0% | $381.79M+17,031% | -$2.26M-107% | $32.48M+136% | ||
| $282.19M+94.3% | $145.22M-62.0% | $381.79M+17,031% | -$2.26M-107% | $32.48M+136% | ||
| 24.2%+10.9pp | 13.2%-17.3pp | 30.6%+30.9pp | -0.3%-5.8pp | 5.5%+20.8pp | ||
| $268.64M+104% | $131.72M-64.2% | $367.98M+2,372% | -$16.2M-190% | $18.08M+117% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Alnylam Pharmaceuticals's revenue?
- Alnylam Pharmaceuticals (ALNY) generated $4.3B in revenue over the trailing twelve months, up 82.6% year over year.
- Is Alnylam Pharmaceuticals profitable?
- Alnylam Pharmaceuticals reported $502.3M in net income over the trailing twelve months, a 11.7% net margin.
- What are Alnylam Pharmaceuticals's profit margins?
- Gross margin is 81.0% and operating margin is 17.5%, with a 11.7% net margin.
- What is Alnylam Pharmaceuticals's earnings per share?
- Alnylam Pharmaceuticals's diluted EPS over the trailing twelve months is $3.66.
- Where does Alnylam Pharmaceuticals's income statement data come from?
- Every line is extracted from Alnylam Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
